الفهرس 
Title : Possible role of farnesoid X receptor in sporadic alzheimer{u2019}s disease model
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
Alzheimer{u2019}s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia. Chenodeoxycholic acid (CDCA) and synthetic Farnesoid X receptors (FXR) ligands have shown promising outcomes in ameliorating insulin resistance and inflammation associated with various medical conditions. This study aimed to investigate the possible role of FXR activation, using CDCA, in the management of AD. Adult male Wistar rats were randomly allocated into five groups and treated for six consecutive weeks; control (vehicle), AD-model (AlCl3 50 mg/kg/day i.p), CDCA-treated group (AlCl3 + CDCA 90 mg/kg/day p.o), chloroquine (CQ)-treated group (AlCl3 + CQ 3 mg/kg i.p) and combination group (AlCl3 + CDCA + CQ), where CDCA and CQ treatment started on day 15. CDCA improved cognition as assessed by Morris Water Maze and Y-maze tests and preserved normal histological features. Moreover, CDCA lowered hippocampal amyloid-beta production and tau hyperphosphorylation. Although no significant difference was observed in hippocampal insulin level, CDCA reduced insulin receptor substrate-1 phosphorylation at serine-307 (pSer307-IRS1), while increased protein kinase B (Akt) activation, glucose transporter type 4 (GLUT4), peroxisome proliferator-activated receptor gamma (PPARÞ) and glucagon-like peptide-1 (GLP-1)